Palo Alto Investors LP Takes Position in Edwards Lifesciences Corporation $EW

Palo Alto Investors LP bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 33,640 shares of the medical research company’s stock, valued at approximately $3,043,074.

Other hedge funds have also made changes to their positions in the company. Empowered Funds LLC acquired a new stake in Edwards Lifesciences in the second quarter worth $3,901,000. United Capital Financial Advisors LLC bought a new position in shares of Edwards Lifesciences during the 2nd quarter valued at about $1,807,000. Old North State Trust LLC bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $278,000. Equitable Holdings Inc. bought a new stake in Edwards Lifesciences in the 2nd quarter valued at $860,000. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter worth $3,584,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE:EW traded up $0.24 during midday trading on Friday, hitting $90.19. 2,043,685 shares of the stock were exchanged, compared to its average volume of 4,699,690. The company has a market capitalization of $51.93 billion, a price-to-earnings ratio of 51.83, a P/E/G ratio of 2.38 and a beta of 0.85. The business has a 50-day moving average price of $89.48 and a two-hundred day moving average price of $84.99. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period last year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insiders Place Their Bets

In related news, VP Annette Bruls sold 2,644 shares of Edwards Lifesciences stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares of the company’s stock, valued at $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 4,501 shares of company stock valued at $408,213. 0.31% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on EW. Royal Bank Of Canada upped their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Evercore reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. Leerink Partners raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $87.00 to $101.00 in a report on Friday, July 24th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.